California Pacific Medical Center Research Institute
cpmc.orgTotal trials
39
Active
4
Phase 3
0
Total enrollment
13,532
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Zoledronic Acid 5Mg/Bag 100Ml Inj | — | — | — | — | — | 1 |
Next readouts
- 2025-10-31
Top conditions
- Metastatic Melanoma4
- Methamphetamine Dependence3
- Methamphetamine Addiction2
- Pancreaticobiliary Cancers1
- Jaundice1
- Bile Duct Obstruction1
- Nasal Congestion1
- Melanoma1
Frequently asked questions about California Pacific Medical Center Research Institute
- How many clinical trials does California Pacific Medical Center Research Institute have on ClinicalTrials.gov?
- California Pacific Medical Center Research Institute is listed as the lead sponsor on 39 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of California Pacific Medical Center Research Institute's trials are in Phase 3?
- 0 of California Pacific Medical Center Research Institute's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does California Pacific Medical Center Research Institute focus on?
- California Pacific Medical Center Research Institute's most-studied conditions on ClinicalTrials.gov are Metastatic Melanoma, Methamphetamine Dependence, Methamphetamine Addiction, Pancreaticobiliary Cancers, Jaundice.
- When are California Pacific Medical Center Research Institute's next clinical trial readouts?
- California Pacific Medical Center Research Institute has 1 upcoming primary-completion readout tracked here; the soonest is “Trial of Parkinson's And Zoledronic Acid”, expected around 2025-10-31.